Albireo Pharma, Inc. (ALBO): Price and Financial Metrics


Albireo Pharma, Inc. (ALBO)

Today's Latest Price: $37.65 USD

0.10 (-0.26%)

Updated Dec 2 4:00pm

Add ALBO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALBO Stock Summary

  • With a price/sales ratio of 59.9, Albireo Pharma Inc has a higher such ratio than 95.93% of stocks in our set.
  • As for revenue growth, note that ALBO's revenue has grown 218.41% over the past 12 months; that beats the revenue growth of 97.09% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ALBO comes in at -28.65% -- higher than that of only 11.39% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Albireo Pharma Inc, a group of peers worth examining would be ARDX, ALPN, CLLS, BBIO, and BLCM.
  • ALBO's SEC filings can be seen here. And to visit Albireo Pharma Inc's official web site, go to www.albireopharma.com.

ALBO Stock Price Chart Interactive Chart >

Price chart for ALBO

ALBO Price/Volume Stats

Current price $37.65 52-week high $49.00
Prev. close $37.75 52-week low $11.26
Day low $37.35 Volume 136,780
Day high $38.57 Avg. volume 193,854
50-day MA $34.67 Dividend yield N/A
200-day MA $27.20 Market Cap 718.25M

Albireo Pharma, Inc. (ALBO) Company Bio


Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.


ALBO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALBO Latest Social Stream


Loading social stream, please wait...

View Full ALBO Social Stream

Latest ALBO News From Around the Web

Below are the latest news stories about Albireo Pharma Inc that investors may wish to consider to help them evaluate ALBO as an investment opportunity.

Albireo raises $160M in public offering

Albireo Pharma (ALBO) has priced its public offering of 4M common shares at $40.00/share, for expected gross proceeds of $160M.Underwriters' over-allotment is an additional 600K shares.Closing date is September 14.Previously: Albireo launches equity offering of 3M shares (Sept. 8)...

Seeking Alpha | September 10, 2020

The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-o...

Benzinga | September 9, 2020

Albireo up 10% ahead of late-stage odevixibat data readout

Thinly traded micro cap Albireo Pharma (ALBO) perks up 10% premarket on light volume ahead of this morning's conference call (8:30 am ET) to discuss top line results from a Phase 3 clinical trial, PEDFIC 1, evaluating lead candidate odevixibat in patients with a rare inherited disorder called progressive familial intrahepatic cholestasis...

Seeking Alpha | September 8, 2020

32 Stocks Moving in Tuesday's Pre-Market Session

Gainers Albireo Pharma, Inc. (NASDAQ: ALBO ) rose 66.2% … Full story available on Benzinga.com

Benzinga | September 8, 2020

Albireo to Present at the William Blair Biotech Focus Conference 2020

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT. The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page o...

Yahoo | July 30, 2020

Read More 'ALBO' Stories Here

ALBO Price Returns

1-mo 18.81%
3-mo 38.98%
6-mo 41.38%
1-year 79.71%
3-year 54.37%
5-year 292.19%
YTD 48.11%
2019 3.63%
2018 -4.18%
2017 44.39%
2016 73.82%
2015 -74.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9381 seconds.